艾伯维医药贸易（上海）有限公司
Corporation · Shanghai, China · LEI 254900D139OL0B7KIR57
LEI lapsed
Summary
艾伯维医药贸易（上海）有限公司 is registered in China and entered in the “National Enterprise Credit Information Publicity System” under number 9131011505300972XA. According to GLEIF, its ultimate parent is ABBVIE INC. (United States), which is also its direct parent. That group has 64 subsidiaries with LEIs in 37 countries, 1 of them in China. The LEI was first issued on 12 Jul 2021 and the record was last updated on 13 Sep 2024. It has lapsed: renewal was due by 20 Oct 2023. AssetCensus found 3 data-quality notes for this entity (see below).
Written from GLEIF data using fixed, reviewed sentence templates.
Data-quality notes (AssetCensus analysis)
- The LEI has lapsed: it was due for renewal by 20 Oct 2023 and was not renewed, so GLEIF's data for this entity has not been re-verified since. A lapsed LEI does not mean the company has ceased to exist.
- The ultimate-parent link rests on accounts for the period ending 30 Dec 2020, more than 24 months before this data release. The group may have changed since.
- The ultimate-parent relationship record was not renewed; it was last updated on 10 Nov 2025.
Company details
| Legal form | Corporation |
|---|---|
| Register | National Enterprise Credit Information Publicity System · Register website |
| Registration number | 9131011505300972XA |
| Registration authority | State Administration for Market Regulation |
| Jurisdiction | China |
| Registered address | Part 418 Floor 4, 458 North Fu Te Road, 200131 Shanghai, China |
| Category | company or other legal entity |
| Status | active |
| Founded (per GLEIF) | 13 Sep 2012 |
| LEI | 254900D139OL0B7KIR57 |
| LEI status | lapsed |
| LEI first issued | 12 Jul 2021 |
| LEI record last updated | 13 Sep 2024 |
| Next LEI renewal | 20 Oct 2023 |
| Corroboration of the LEI record | fully corroborated |
Group membership
艾伯维医药贸易（上海）有限公司 this entity
Relationship to the parent
| Direct parent | Ultimate parent | |
|---|---|---|
| Parent | ABBVIE INC. | ABBVIE INC. |
| Accounting period | 31 Dec 2019 to 30 Dec 2020 | 31 Dec 2019 to 30 Dec 2020 |
| Evidence | other official documents | other official documents |
| Corroboration | supplied by the entity only | supplied by the entity only |
| Consolidation percentage reported to GLEIF | 100.00% | 100.00% |
| Relationship start | 31 Dec 2012 | 31 Dec 2012 |
| Recorded at GLEIF since | 12 Jul 2021 | 12 Jul 2021 |
| Last updated | 10 Nov 2025 | 10 Nov 2025 |
| Record status | not renewed | not renewed |
Other subsidiaries of the same direct parent (59)
- AbbVie A/S Denmark lapsed
- AbbVie AG Switzerland lapsed
- AbbVie AS Norway lapsed
- AbbVie B.V. Netherlands lapsed
- AbbVie Bahamas Ltd. Bahamas lapsed
- AbbVie Biopharmaceuticals GmbH Switzerland
- ABBVIE BIOTECHNOLOGY LTD Bermuda
- AbbVie Central Finance B.V. Netherlands
- AbbVie Corporation Canada
- ABBVIE D.O.O. Slovenia lapsed
- AbbVie Deutschland GmbH And Co. KG Germany lapsed
- Abbvie Endocrine Inc. United States lapsed